Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice

Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia Submitted 11 December 2007 ; accepted in final form 14 January 2008 We tested the hypothesis that chronic treatment with sildenafil attenuates myocardial infarction (MI)-induced heart failur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of physiology. Heart and circulatory physiology 2008-03, Vol.294 (3), p.H1398-H1406
Hauptverfasser: Salloum, Fadi N, Abbate, Antonio, Das, Anindita, Houser, Jon-Erik, Mudrick, Colin A, Qureshi, Ian Z, Hoke, Nicholas N, Roy, Sion K, Brown, William R, Prabhakar, Shashi, Kukreja, Rakesh C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia Submitted 11 December 2007 ; accepted in final form 14 January 2008 We tested the hypothesis that chronic treatment with sildenafil attenuates myocardial infarction (MI)-induced heart failure. Sildenafil has potent protective effects against necrosis and apoptosis following ischemia-reperfusion in the intact heart and cardiomyocytes. ICR mice underwent MI by left anterior descending coronary artery ligation and were treated with sildenafil (0.71 mg/kg bid) or saline for 4 wk. Infarct size (IS) was measured 24 h postinfarction, and apoptosis was measured by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. Left ventricular end-diastolic diameter (LVEDD) and fractional shortening (FS) were measured by echocardiography. Sildenafil reduced IS (40.0 ± 4.6%) compared with that in saline (69.6 ± 4.1%, P < 0.05). N G -nitro- L -arginine methyl ester, a nitric oxide synthase (NOS) inhibitor (15 mg/kg bid), blocked the protective effect of sildenafil (IS, 60.2 ± 1.6%, P < 0.05 vs. sildenafil). Western blot analysis revealed a significant increase in endothelial NOS/inducible NOS proteins 24 h post-MI after treatment with sildenafil versus saline. Apoptosis decreased from 2.4 ± 0.3% with saline to 1.2 ± 0.1% with sildenafil ( P < 0.05) on day 7 and from 2.0 ± 0.2% with saline to 1.2 ± 0.1% with sildenafil on day 28 ( P < 0.05), which was associated with an early increase in the Bcl-2-to-Bax ratio. LVEDD increased from baseline value of 3.6 ± 0.1 to 5.2 ± 0.2 and to 5.5 ± 0.1 mm on days 7 and 28 , respectively, with saline ( P < 0.05) but was attenuated to 4.4 ± 0.2 and 4.4 ± 0.1 mm following sildenafil treatment on days 7 and 28 , respectively ( P > 0.05 vs. baseline). FS significantly improved post-MI with sildenafil. A marked decline in cardiac hypertrophy was observed with sildenafil, which paralleled a reduction in pulmonary edema. Survival rate was lower with saline (36%) compared with sildenafil (93%, P < 0.05). Sildenafil attenuates ischemic cardiomyopathy in mice by limiting necrosis and apoptosis and by preserving left ventricular function possibly through a nitric oxide-dependent pathway. phosphodiesterase inhibitors; heart failure; ischemic injury; vasodilatation; nitric oxide; guanosine 3',5'-cyclic monophosphate; apoptosis; remodeling Address for reprint requests and other correspondence: R. C. Kukreja, Div. of Cardiology, Bo
ISSN:0363-6135
1522-1539
DOI:10.1152/ajpheart.91438.2007